Ultragenyx Pharmaceutical
RARE
236 hedge funds and large institutions have $3.87B invested in Ultragenyx Pharmaceutical in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 94 increasing their positions, 75 reducing their positions, and 23 closing their positions.
91% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 23
54% more capital invested
Capital invested by funds: $2.52B → $3.87B (+$1.36B)
25% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 75
8% more funds holding
Funds holding: 219 → 236 (+17)
0.1% less ownership
Funds ownership: 98.74% → 98.64% (-0.1%)
1% less call options, than puts
Call options by funds: $23.1M | Put options by funds: $23.4M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| 1 |
Sands Capital Management
Arlington,
Virginia
|
+$59.7M |
| 2 |
RI
RTW Investments
New York
|
+$57.5M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$56.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.8M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$36.2M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
251
Prudential Financial
Newark,
New Jersey
| – | -$228K | -6,409 | Closed |
|
252
D.E. Shaw & Co
New York
| – | -$219K | -6,152 | Closed |
|
|
HT
253
Headlands Technologies
Chicago,
Illinois
| – | -$119K | -3,351 | Closed |
|
|
EIM
254
Essex Investment Management
Boston,
Massachusetts
| – | -$52.8K | -1,481 | Closed |
|
|
CG
255
Cutler Group
San Francisco,
California
| – | -$36K | -1,010 | Closed |
|
|
SSG
256
Summit Securities Group
New York
| – | -$23K | -657 | Closed |
|
257
Loomis, Sayles & Company
Boston,
Massachusetts
| – | -$5K | -152 | Closed |
|
|
IA
258
IFP Advisors
Tampa,
Florida
| – | -$2.6K | -73 | Closed |
|
|
CA
259
Crewe Advisors
Salt Lake City,
Utah
| – | -$107 | -3 | Closed |
|
RARE Hedge Fund Activity: Q4 2023 in Review
236 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2023, worth a combined $3.87B — up 54% from $2.52B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new RARE positions and 23 closed out — a net gain of 21 holders — while 94 added to existing stakes and 75 trimmed.
The largest buyer was Sands Capital Management, adding an estimated $59.7M. The largest seller was Avoro Capital Advisors, cutting an estimated $44.6M.
- 236 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2023, up from 219 in Q3 2023.
- Funds reported $3.87B of Ultragenyx Pharmaceutical stock for Q4 2023, up 54% quarter-over-quarter.
- 44 funds opened new Ultragenyx Pharmaceutical positions in Q4 2023 and 23 closed out, a net change of +21 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q4 2023 was Sands Capital Management, an estimated $59.7M added.
- The largest Ultragenyx Pharmaceutical seller in Q4 2023 was Avoro Capital Advisors, an estimated $44.6M sold.
Based on aggregated 13F filings for Q4 2023.